Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235914 | 0.99 | NAAA (0.57) | NAAAHPGDTLR2RENCYP2D6 | |
| SCHEMBL2235923 | 0.99 | NAAA (0.57) | NAAAHPGDTLR2RENCYP2D6 | |
| Trifluoroacetic Acid SCHEMBL22287294 | 0.94 | NAAA (0.49) | NAAAHPGDTLR2RENCYP2D6 | |
| SCHEMBL9551243 | 0.93 | KMT2A (0.51) | NAAACYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL14567237 | 0.82 | KMT2A (0.49) | CYP2D6CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL987955 | 0.80 | DPP7 (0.58) | NAAAHPGDTLR2REN | |
| SCHEMBL19728216 | 0.80 | CYP3A4 (0.68) | NAAAHPGDTLR2RENCYP2D6 | |
| SCHEMBL26945686 | 0.80 | CYP3A4 (0.68) | NAAAHPGDTLR2RENCYP2D6 | |
| SCHEMBL16994019 | 0.80 | DPP7 (0.58) | NAAAHPGDTLR2REN | |
| SCHEMBL8914559 | 0.79 | NAAA (0.59) | NAAAHPGDTLR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240076269-A1 | KCNQ POTENTIATORS | Eii Lilly and Company (US) | 2024-03-07 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3921030-B1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | LILLY CO ELI (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3921030-B1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | LILLY CO ELI (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220073464-A1 | KCNQ POTENTIATORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-20220073464-A1 | KCNQ POTENTIATORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-11208383-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200247752-A1 | KCNQ Potentiators | ELI LILLY AND COMPANY (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-20200247752-A1 | KCNQ Potentiators | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-11840516-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-20240076269-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-11208383-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
| US-20220073464-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | NAAA 3342/4885HPGD 3538/4885TLR2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.